Cerca
image du produit
American Heart Journal

Abbonarsi

Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3 - 08/12/22

Doi : 10.1016/j.ahj.2022.10.009 
Muhammad Sabbah, MD a, Karsten Veien, MD b, Matti Niemela, MD c, Phillip Freeman, MD, PhD d, Rickard Linder, MD, PhD, FESC e, f, Dan Ioanes, MD g, Christian Juhl Terkelsen, MD, DMSc h, i, Olli A. Kajander, MD, PhD j, Sasha Koul, MD k, Mikko Savontaus, MD l, Pasi Karjalainen, MD, PhD j, Andrejs Erglis, MD m, Mikko Minkkinen, MD j, Troels Jørgensen, MD, PhD a, Lars Sondergaard, MD, PhD, DMSc a, n, Ole De Backer, MD, PhD a, Thomas Engstrøm, MD, PhD, DMSc a, n, Jacob Lønborg, MD, PhD, DMSc a, ⁎
a Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark 
b Department of Cardiology, Odense University Hospital, Odense, Denmark 
c Department of Cardiology, Oulu University Hospital, University of Oulu, Finland 
d Department of Cardiology, Aalborg University Hospital, Denmark 
e Department of Medicine, Karolinska Institutet, Stockholm, Sweden 
f Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden 
g Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden 
h The Danish Heart Foundation 
i Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark 
j Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland 
k Department of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden 
l Heart Center, Turku University Hospital, Finland 
m University of Latvia, Riga, Latvia 
n Department of Clinical Medicine, University of Copenhagen, Denmark 

⁎Reprint requests: Jacob Lønborg, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark.Inge Lehmanns Vej 7Copenhagen2100Denmark

Riassunto

Background

Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes.

Study design

The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI.

Summary

NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

    •

  • Contenuto

    •

Vol 255

P. 39-51 - Gennaio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Reducing ethnic and racial disparities by improving undertreatment, control, and engagement in blood pressure management with health information technology (REDUCE-BP) hybrid effectiveness-implementation pragmatic trial: Rationale and design
  • Julie C. Lauffenburger, Rasha Khatib, Alvia Siddiqi, Michelle A. Albert, Punam A. Keller, Lipika Samal, Nicole Glowacki, Marlon E. Everett, Kaitlin Hanken, Simin G. Lee, Gauri Bhatkhande, Nancy Haff, Ellen S. Sears, Niteesh K. Choudhry
| Articolo seguente Articolo seguente
  • The patient-reported outcome measurement in heart failure clinic trial: Rationale and methods of the PRO-HF trial
  • Neil M. Kalwani, Jamie Calma, George M. Varghese, Anshal Gupta, Jimmy Zheng, Cati Brown-Johnson, Alexis Amano, Stacie Vilendrer, Marcy Winget, Steven M. Asch, Paul Heidenreich, Alexander Sandhu

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account

Aide & support

Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.

Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.